C0003641||Aprotinin
C0040613||tranexamic acid
C0010055||coronary artery bypass surgery
C1518527||multicentre observational study
C0003641||Aprotinin
C0019080||bleeding
C0371802||transfusion of blood products
C0243095||high-transfusion-risk
C0018787||cardiac
C0010055||isolated coronary artery bypass graft (CABG) surgery
C0008976||head-to-head trials
C1707887||compare the efficacies
C1705187||safety
C0003641||aprotinin
C0040613||tranexamic acid
C0040613||tranexamic acid
C0010055||coronary artery bypass graft
C1516606||before-and-after study pooling individual data
C1096775||published trials
C0242356||databases
C0337954||tertiary care teaching hospitals
C0019994||Bichat-Claude Bernard Hospital
C0030561||Paris
C0019994||Laennec Hospital
C0010055||CABG surgery
C0003641||aprotinin
C0003641||tranexamic acid
C0032788||blood loss
C0543467||operation
C0371802||transfusion of blood products
C0035110||reoperation for bleeding
C0206074||renal replacement therapy
C0032788||blood loss after surgery
C4075673||requiring intraoperative blood product transfusion
C0003641||aprotinin
C0035110||reoperations for bleeding
C0206074||renal replacement therapy
C0003641||aprotinin
C0010055||isolated CABG
C0003641||aprotinin
C0003641||tranexamic acid
C0032788||postoperative blood loss
C0003641||aprotinin
C0019080||major blood loss
C0005841||transfusion
C0010055||CABG surgery